The association of direct thrombin inhibitor anticoagulants with cardiac thromboses.

Abstract

Direct thrombin inhibitor (anti-factor IIa) anticoagulants, now established for treatment and prevention of cardiac thromboembolism and VTE, have been repeatedly associated with a significantly increased frequency of thrombosis on abnormal cardiac endothelium when compared head-to-head with indirectly acting therapeutic anticoagulants in studies of sufficient patient number and duration. Although there is uncertainty as to the mechanism, the weight of evidence as a class effect warrants prescribing effective anticoagulants other than direct thrombin inhibitors.

• Authors: Bruce L Davidson
• Journal: Chest (Chest) Vol. 147 Issue 1 Pg. 21-24 (Jan 2015) ISSN: 1931-3543 [Electronic] United States
• PMID: 25254608 (Publication Type: Journal Article, Review)

Chemical References

• Anticoagulants
• Thrombin

Topics

• Anticoagulants (therapeutic use)
• Heart Diseases (blood, drug therapy)
• Humans
• Thrombin (antagonists & inhibitors, metabolism)
• Thrombosis (blood, drug therapy)